Foley Advocaten publiceren overzicht van cruciaal jaar voor 340B-programma voor geneesmiddelenprijzen

Foley & Lardner LLP partners Anil Shankar and Adria Warren and associate Jordan Smiley authored the Pharmaceutical Commerce article, “Critical Year Ahead for the 340B Drug Pricing Program.”

In the article, the authors provide an introduction to the 340B Drug Pricing Program’s recent history of legal and regulatory challenges, key trends, and potential future developments.

“Monitoring judicial decisions and regulatory guidance is essential, especially with the potential for congressional involvement via the SUSTAIN 340B Act, and with new revisions to HRSA’s Administrative Dispute Resolution process for hearing disputes related to the 340B Program,” the authors conclude. “Staying abreast of these developments allows for proactive compliance and strategic adaptation to changes in the legal and regulatory landscape.”